RCUS
Price:
$24.31
Market Cap:
$2.45B
Arcus Biosciences, Inc. is a U.S.-based, clinical-stage biopharmaceutical company dedicated to discovering and commercializing innovative cancer therapies. Its pipeline features several promising drug candidates: Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, is currently in Phase 1b/2 clinical trials. Zimberelimab, an anti-PD-1 antibody, is being evaluated as a monotherapy in Phase 1b studies. Another key asset is Domvanalimab, an anti-TIGIT monoclonal antibody, undergoing Phase 2 development for first-line metastatic non-small cell lung cancer when administered with Zimberelimab. The company is also developing Quemliclustat, a small-molecule CD73 inhibitor, in Phase 1/1b studi...[Read more]
Industry
Biotechnology
IPO Date
2018-03-15
Stock Exchange
NYSE
Ticker
RCUS
According to Arcus Biosciences, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -7.67. This represents a change of -194.57% compared to the average of 8.11 of the last 4 quarters.
The mean historical PE Ratio of Arcus Biosciences, Inc. over the last ten years is -2.56. The current -7.67 PE Ratio has changed 29.83% with respect to the historical average. Over the past ten years (40 quarters), RCUS's PE Ratio was at its highest in in the September 2020 quarter at 142.83. The PE Ratio was at its lowest in in the March 2024 quarter at -99.57.
Average
-2.56
Median
-6.54
Minimum
-23.29
Maximum
53.25
Discovering the peaks and valleys of Arcus Biosciences, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 108.76%
Maximum Annual PE Ratio = 53.25
Minimum Annual Increase = -536.91%
Minimum Annual PE Ratio = -23.29
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -7.24 | 52.74% |
| 2024 | -4.74 | 3.03% |
| 2023 | -4.60 | -17.43% |
| 2022 | -5.57 | -110.47% |
| 2021 | 53.25 | -536.91% |
| 2020 | -12.19 | 108.76% |
| 2019 | -5.84 | -22.48% |
| 2018 | -7.53 | -4.31% |
| 2017 | -7.87 | -66.20% |
The current PE Ratio of Arcus Biosciences, Inc. (RCUS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-5.53
5-year avg
6.22
10-year avg
-2.56
Arcus Biosciences, Inc.’s PE Ratio is greater than ImmunityBio, Inc. (-8.62), greater than Denali Therapeutics Inc. (-8.09), less than Galapagos N.V. (3.32), greater than Cogent Biosciences, Inc. (-11.21), greater than 89bio, Inc. (-7.78), less than Agios Pharmaceuticals, Inc. (-4.71), less than Viridian Therapeutics, Inc. (-4.78), greater than Beam Therapeutics Inc. (-53.34), less than Ocular Therapeutix, Inc. (-6.46), less than Liquidia Corporation (297.24),
| Company | PE Ratio | Market cap |
|---|---|---|
| -8.62 | $7.71B | |
| -8.09 | $3.70B | |
| 3.32 | $1.84B | |
| -11.21 | $5.90B | |
| -7.78 | $2.20B | |
| -4.71 | $2.03B | |
| -4.78 | $1.50B | |
| -53.34 | $3.51B | |
| -6.46 | $2.06B | |
| 297.24 | $6.32B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arcus Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Arcus Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Arcus Biosciences, Inc.'s PE Ratio?
How is the PE Ratio calculated for Arcus Biosciences, Inc. (RCUS)?
What is the highest PE Ratio for Arcus Biosciences, Inc. (RCUS)?
What is the 3-year average PE Ratio for Arcus Biosciences, Inc. (RCUS)?
What is the 5-year average PE Ratio for Arcus Biosciences, Inc. (RCUS)?
How does the current PE Ratio for Arcus Biosciences, Inc. (RCUS) compare to its historical average?